Cardiva VASCADE 6/7F VCS
Device Devices
PDI M729700580I0
General payments
$1,024,794
Research payments
$175,013
Through program year 2025, $1,024,794 in general payments and $175,013 in research payments were reported against Cardiva VASCADE 6/7F VCS (Devices).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
7 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $138,623 | 1,260 |
| 2024 | General | $77,667 | 1,013 |
| 2023 | General | $89,062 | 2,409 |
| 2022 | General | $118,230 | 2,022 |
| 2022 | Research | $55,013 | 1 |
| 2021 | General | $601,213 | 388 |
| 2021 | Research | $120,000 | 2 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 53 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 40 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
7,092 general · 3 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.